French software maker Dassault Systemes (DAST.PA) is in talks to buy drug-trial software maker ArisGlobal from Nordic Capital for about $2 billion, the Financial Times reported, citing people familiar with the matter. The potential deal would extend Dassault Systemes’ foray into software used in life sciences and would rank as its second-biggest acquisition after its $5.8 billion takeover of clinical trial software group Medidata Solutions in 2019, the report said. A transaction between the two firms is not a foregone conclusion, and talks could still fall apart, FT said.
Read the full article: Dassault Systemes in Talks to Buy Drug Trial Software Firm ArisGlobal, FT Reports //
Source: https://www.reuters.com/business/healthcare-pharmaceuticals/dassault-systemes-talks-buy-drug-trial-software-firm-arisglobal-ft-reports-2026-07-16/